Evaluation of hepatitis C virus antibody assay using dried blood spot samples

• Published in: Scientific reports Vol. 12; no. 1; p. 3763
• Main Authors: Holzmayer, Vera, Taylor, Russell, Kuhns, Mary C., Gawel, Susan H., Ndembi, Nicaise, Mbanya, Dora, Kaptue, Lazare, Rodgers, Mary A., Cloherty, Gavin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.03.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/255/234/2513; 692/308/174; 692/700/139/1420; Blood; Dried Blood Spot Testing; Hepacivirus; Hepatitis; Hepatitis C; Hepatitis C - diagnosis; Hepatitis C Antibodies; Humanities and Social Sciences; Humans; multidisciplinary; Retrospective Studies; Science; Science (multidisciplinary); Sensitivity and Specificity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-07821-0

Early diagnosis of hepatitis C virus (HCV) infection is essential for prompt initiation of treatment and prevention of transmission, yet several logistical barriers continue to limit access to HCV testing. Dried blood spot (DBS) technology involves a simple fingerstick that eliminates the need for trained personnel, and DBS can be stored and transported at room temperature. We evaluated the use of DBS whole blood samples in the modified Abbott ARCHITECT anti-HCV assay, comparing assay performance against the standard assay run using DBS and venous plasma samples. 144 HCV positive and 104 HCV negative matched venous plasma and whole blood specimens were selected from a retrospective study with convenience sampling in Cameroon. Results obtained using a modified volume DBS assay were highly correlated to the results of the standard assay run with plasma on clinical samples and dilution series (R 2  = 0.71 and 0.99 respectively). The ARCHITECT Anti-HCV assay with input volume modification more accurately detects HCV antibodies in DBS whole blood samples with 100% sensitivity and specificity, while the standard assay had 90.97% sensitivity. The use of DBS has the potential to expand access to HCV testing to underserved or marginalized populations with limited access to direct HCV care.